438 results on '"Ruilope, Luis"'
Search Results
2. THREE-YEAR NIGHTTIME BLOOD PRESSURE REDUCTIONS AFTER RADIOFREQUENCY RENAL DENERVATION IN PATIENTS WITH UNCONTROLLED HYPERTENSION AND CHRONIC KIDNEY DISEASE
3. PREDICTION OF CARDIOVASCULAR EVENTS IN HYPERTENSIVE SUBJECTS WITH ARTIFICIAL INTELLIGENCE TOOLS
4. RELATIONSHIP BETWEEN CLINIC AND AMBULATORY BLOOD PRESSURE AND MORTALITY IN PATIENTS WITH PREVIOUS STROKE
5. THE PROGNOSTIC POWER OF DIASTOLIC-TO-SYSTOLIC ARTERIAL STIFFENING IS GREATER AT NIGHTTIME IN MIDDLE-AGE PATIENTS UNDERGOING 24-HOUR AMBULATORY BLOOD PRESSURE MONITORING
6. ASSOCIATION OF CLINIC AND AMBULATORY BLOOD PRESSURE WITH MORTALITY IN PATIENTS WITH AND WITHOUT DIABETES
7. Commentary on ‘Prevalence and factors associated with masked hypertension in chronic kidney disease’
8. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
9. Renal denervation in the antihypertensive arsenal – knowns and known unknowns
10. A blunted nocturnal blood pressure decline is associated with all-cause and cardiovascular mortality.
11. Early renal and vascular damage within the normoalbuminuria condition
12. Association of clinic and ambulatory heart rate parameters with mortality in hypertension
13. Impact of timing of antihypertensive treatment on mortality: an observational study from the Spanish Ambulatory Blood Pressure Monitoring Registry.
14. Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials
15. S-09-3: ROLE OF SACUBITRIL/VALSARTAN IN THE CONTROL OF BLOOD PRESSURE
16. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: ESC/ESH Task Force for the Management of Arterial Hypertension
17. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes
18. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension
19. Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part II: Role in disease conditions: a joint consensus statement from the European Society of Hypertension Working Group on Endothelin and Endothelial Factors and the Japanese Society of Hypertension
20. Endothelial factors in the pathogenesis and treatment of chronic kidney disease Part I: General mechanisms: a joint consensus statement from the European Society of Hypertension Working Group on Endothelin and Endothelial Factors and The Japanese Society of Hypertension
21. White-coat UnControlled Hypertension, Masked UnControlled Hypertension, and True UnControlled Hypertension, phonetic and mnemonic terms for treated hypertension phenotypes
22. Blood pressure variability is increasing from the first to the second day of the interdialytic interval in hemodialysis patients
23. Predictors for the development of microalbuminuria and interaction with renal function
24. Prevalence and clinical characteristics of white-coat hypertension based on different definition criteria in untreated and treated patients
25. IMBALANCE IN BONE MORPHOGENIC PROTEINS 2 AND 7 IS ASSOCIATED WITH HYPERTENSION AND ARTERIAL STIFFNESS IN CHRONIC KIDNEY DISEASE
26. NOCTURNAL BLOOD PRESSURE, NOCTURNAL DIPPING, AND MORTALITY
27. BLOOD PRESSURE REDUCTION AFTER CATHETER-BASED RENAL DENERVATION IN PATIENTS WITH CARDIOVASCULAR DISEASE IN THE GLOBAL SYMPLICITY REGISTRY
28. TIME DOSING OF ANTIHYPERTENSIVE TREATMENT AND PROGNOSIS
29. Reply
30. Renal artery denervation for treatment of patients with self-reported obstructive sleep apnea and resistant hypertension: results from the Global SYMPLICITY Registry
31. Antihypertensive therapy and short-term blood pressure variability
32. Antihypertensive drugs and the risk of cancer: a critical review of available evidence and perspective
33. Antihypertensive therapy and short-term blood pressure variability.
34. A2519 Renoprotective effect of angiotensin receptor blockers beyond their BP lowering effect in patients with hypertension and chronic kidney disease
35. A4699 Effects of renal denervation in patients with versus without chronic kidney disease
36. A2492 Application of redox proteomics to stratified cardiovascular risk in young population
37. A4708 Finerenone improves endothelial function through the increase in nitric oxide availability in a rat model of chronic kidney disease
38. Antihypertensive drug use in resistant and nonresistant hypertension and in controlled and uncontrolled resistant hypertension
39. Blood pressure variability increases with advancing chronic kidney disease stage
40. Expertise
41. 24-h pulse pressure cutoff point definition by office pulse pressure in a population of Spanish older hypertensive patients
42. Hypertension in dialysis patients
43. Renal denervation reduces office and ambulatory heart rate in patients with uncontrolled hypertension
44. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension.
45. PS 11-84 HYPERTENSION TREATMENT BASED ON NON-INVASIVE IMPEDANCE CARDIOGRAPHY
46. PS 17-43 HEARING IMPAIRMENT IN DIABETES
47. PROGNOSIS OF RESISTANT HYPERTENSION, WHITE-COAT RESISTANT HYPERTENSION, AND REFRACTORY HYPERTENSION.
48. Salutary cardiovascular effects of antidiabetic drugs
49. Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes
50. Development of albuminuria and enhancement of oxidative stress during chronic renin–angiotensin system suppression
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.